Not exact matches
The company's lead product candidate, dilanubicel (NLA101), is currently being evaluated in two ongoing
Phase 2 clinical trials in adult and pediatric patients with hematologic malignancies undergoing an
allogeneic transplant and adult patients receiving high dose chemotherapy for Acute Myeloid Leukemia.
The resulting 2724 trials were then categorized and core information collated, including: trial
phase, cell source (autologous /
allogeneic), current activity of the trial and responsible national regulatory agency.
Allogeneic Sibling Donor Peripheral Blood Stem Cells Transplantation With Myeloablative Conditioning for Chronic Myeloid Leukemia in Blast Crisis - Successful Treatment Despite Severe
Phase of the Disease
Bornhäuser M, Kienast J, Trenschel R, et al Reduced - intensity conditioning versus standard conditioning before
allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open - label randomised
phase 3 trial.
Low - dose donor CD8 + cells in the CD4 - depleted graft prevent
allogeneic marrow graft rejection and severe graft - versus - host disease for chronic myeloid leukemia patients in first chronic
phase.
A
phase II study of
allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
Low - Dose ATLG Prevents GVHD in Pediatric Hematologic Malignancies: A newly published randomized
phase III study of pediatric patients showed lower doses of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies undergoing
allogeneic hematopoietic stem cell transplantation from an unrelated donor.
Ponatinib Extends Survival Over Transplant in Chronic
Phase CML: The results of a new study that included patients from the PACE trial and the European Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with allogeneic stem cell transplantation (allo - SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I muta
Phase CML: The results of a new study that included patients from the PACE trial and the European Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with
allogeneic stem cell transplantation (allo - SCT) in patients with chronic
phase chronic myeloid leukemia (CP - CML) with a T315I muta
phase chronic myeloid leukemia (CP - CML) with a T315I mutation.